Literature DB >> 11120948

Effects of mutations in ribosomal protein L16 on susceptibility and accumulation of evernimicin.

P M McNicholas1, P A Mann, D J Najarian, L Miesel, R S Hare, T A Black.   

Abstract

Chemical mutagenesis of Staphylococcus aureus RN450 generated two strains that displayed a stable reduction (30- to 60-fold) in susceptibility to evernimicin. Cell-free translation reactions demonstrated that the resistance determinant was located in the ribosomal fraction. Compared to ribosomes isolated from a wild-type strain, ribosomes from the mutant strains displayed an 8- to 10-fold reduction in affinity for [(14)C]evernimicin. In contrast, the mutants displayed no alteration in either binding affinity or in vitro susceptibility to erythromycin. Exponential cultures of the mutant strains accumulated significantly less [(14)C]evernimicin than the wild-type strain, suggesting that accumulation is dependent on the high affinity that evernimicin displays for its binding site. Sequencing rplP (encodes ribosomal protein L16) in the mutant strains revealed a single base change in each strain, which resulted in a substitution of either cysteine or histidine for arginine at residue 51. Introduction of a multicopy plasmid carrying wild-type rplP into the mutant strains restored sensitivity to evernimicin, confirming that the alterations in rplP were responsible for the change in susceptibility. Overexpression of the mutant alleles in S. aureus RN450 had no effect on susceptibility to evernimicin, demonstrating that susceptibility is dominant over resistance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11120948      PMCID: PMC90243          DOI: 10.1128/AAC.45.1.79-83.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  EVERNINOMICIN, A NEW ANTIBIOTIC COMPLEX FROM MICROMONOSPORA CARBONACEA.

Authors:  M J WEINSTEIN; G M LUEDEMANN; E M ODEN; G H WAGMAN
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1964

2.  An in vitro coupled transcription-translation system from Staphylococcus aureus.

Authors:  R Mahmood; P Compagnone-Post; S A Khan
Journal:  Gene       Date:  1991-09-30       Impact factor: 3.688

3.  Ribosomal components neighboring the 2475 loop in Escherichia coli 50S subunits.

Authors:  P Muralikrishna; B S Cooperman
Journal:  Biochemistry       Date:  1995-01-10       Impact factor: 3.162

4.  Presence of variations in ribosomal protein L16 corresponding to susceptibility of enterococci to oligosaccharides (Avilamycin and evernimicin).

Authors:  F M Aarestrup; L B Jensen
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

5.  Evernimicin (SCH27899) inhibits a novel ribosome target site: analysis of 23S ribosomal DNA mutants.

Authors:  P V Adrian; C Mendrick; D Loebenberg; P McNicholas; K J Shaw; K P Klugman; R S Hare; T A Black
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

6.  Molecular cloning and expression of Bacillus licheniformis beta-lactamase gene in Escherichia coli and Bacillus subtilis.

Authors:  O Gray; S Chang
Journal:  J Bacteriol       Date:  1981-01       Impact factor: 3.490

7.  Amino acid substitutions in protein biosynthesis. Poly(A)-directed polyphenylalanine synthesis.

Authors:  J M Pezzuto; S M Hecht
Journal:  J Biol Chem       Date:  1980-02-10       Impact factor: 5.157

8.  Ribosomal protein gene sequence changes in erythromycin-resistant mutants of Escherichia coli.

Authors:  H S Chittum; W S Champney
Journal:  J Bacteriol       Date:  1994-10       Impact factor: 3.490

9.  Association between decreased susceptibility to a new antibiotic for treatment of human diseases, everninomicin (SCH 27899), and resistance to an antibiotic used for growth promotion in animals, avilamycin.

Authors:  F M Aarestrup
Journal:  Microb Drug Resist       Date:  1998       Impact factor: 3.431

10.  Identification of the chloramphenicol-binding protein in Escherichia coli ribosomes by partial reconstitution.

Authors:  D Nierhaus; K H Nierhaus
Journal:  Proc Natl Acad Sci U S A       Date:  1973-08       Impact factor: 11.205

View more
  9 in total

1.  Mutations in ribosomal protein L16 and in 23S rRNA in Enterococcus strains for which evernimicin MICs differ.

Authors:  Myriam Zarazaga; Carmen Tenorio; Rosa Del Campo; Fernanda Ruiz-Larrea; Carmen Torres
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Interaction of avilamycin with ribosomes and resistance caused by mutations in 23S rRNA.

Authors:  Christine B Kofoed; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  iTRAQ®-based quantitative proteomics reveals the proteomic profiling of methicillin-resistant Staphylococcus aureus-derived extracellular vesicles after exposure to imipenem.

Authors:  Jichun Wang; Junrui Wang; Yanyan Wang; Peng Sun; Xiaohui Zou; Luo Ren; Chunxia Zhang; Enmei Liu
Journal:  Folia Microbiol (Praha)       Date:  2020-11-09       Impact factor: 2.099

4.  Avilamycin and evernimicin induce structural changes in rProteins uL16 and CTC that enhance the inhibition of A-site tRNA binding.

Authors:  Miri Krupkin; Itai Wekselman; Donna Matzov; Zohar Eyal; Yael Diskin Posner; Haim Rozenberg; Ella Zimmerman; Anat Bashan; Ada Yonath
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-19       Impact factor: 11.205

5.  Differential effects of thiopeptide and orthosomycin antibiotics on translational GTPases.

Authors:  Aleksandra Mikolajka; Hanqing Liu; Yuanwei Chen; Agata L Starosta; Viter Márquez; Marina Ivanova; Barry S Cooperman; Daniel N Wilson
Journal:  Chem Biol       Date:  2011-05-27

6.  Structures of the orthosomycin antibiotics avilamycin and evernimicin in complex with the bacterial 70S ribosome.

Authors:  Stefan Arenz; Manuel F Juette; Michael Graf; Fabian Nguyen; Paul Huter; Yury S Polikanov; Scott C Blanchard; Daniel N Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-21       Impact factor: 11.205

Review 7.  Bioactive oligosaccharide natural products.

Authors:  Emilianne K McCranie; Brian O Bachmann
Journal:  Nat Prod Rep       Date:  2014-08       Impact factor: 13.423

8.  The DYW Subgroup PPR Protein MEF35 Targets RNA Editing Sites in the Mitochondrial rpl16, nad4 and cob mRNAs in Arabidopsis thaliana.

Authors:  Nadja Brehme; Eszter Bayer-Császár; Franziska Glass; Mizuki Takenaka
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

9.  Proteomic Analyses of Acinetobacter baumannii Clinical Isolates to Identify Drug Resistant Mechanism.

Authors:  Ping Wang; Ren-Qing Li; Lei Wang; Wen-Tao Yang; Qing-Hua Zou; Di Xiao
Journal:  Front Cell Infect Microbiol       Date:  2021-02-24       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.